Like cancer, placental cells multiply rapidly, invade tissues, and evade destruction by the immune system, but maternal ...

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical ...

High-risk neuroblastoma kills roughly half of affected children because the tumor can switch cell identity and evade therapy.

In a recent study published in Developmental Cell, researchers at Karolinska Institutet created a comprehensive map of ...

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Optieum ...

MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A ...

TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is deepening its collaboration with ...

Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies, Inc. (Optieum), a preclinical stage company dedicated to the discovery and ...

Mammary gland fibroblasts are highly plastic and transition through distinct states during development and disease. A new study by Pascual et al (2025) provides a comprehensive single-cell atlas of ...

This review explores the role of PET in imaging immune activation, particularly in oncology. 18F-FDG is widely used for assessing treatment response to immunotherapies and can demonstrate unique ...

"FAP-α is expressed directly on certain tumors as well as on cells that form the stroma, a part of the tumor microenvironment ... radiopharmaceuticals to provide innovative therapies for cancer ...